Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term prostate-cancer. Found 28 abstracts

no pagination
Levy MH, Adolph MD, Back A, Block S, Codada SN, Dalal S, Deshields TL, Dexter E, Dy SM, Knight SJ, Misra S, Ritchie CS, Sauer TM, Smith T, Spiegel D, Sutton L, Taylor RM, Temel J, Thomas J, Tickoo R, Urba SG, Von Roenn JH, Weems JL, Weinstein SM, Freedman-Cass DA, Bergman MA. Palliative Care. Journal of the National Comprehensive Cancer Network. 2012 Oct;10(10):1284-309.   PMCID: not NIH funded
Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang RG. ALDH1A1 Is a Novel EZH2 Target Gene in Epithelial Ovarian Cancer Identified by Genome-Wide Approaches. Cancer Prevention Research. 2012 Mar;5(3):484-91.   PMCID: PMC3294119
Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li TY, Hua X, Landen CN, Birrer MJ, Sanchez-Beato M, Zhang RG. SUZ12 Promotes Human Epithelial Ovarian Cancer by Suppressing Apoptosis via Silencing HRK. Molecular Cancer Research. 2012 Nov;10(11):1462-72.   PMCID: PMC 3501543
Anderson KS, Sibani S, Wallstrom G, Qiu J, Mendoza EA, Raphael J, Hainsworth E, Montor WR, Wong J, Park JG, Lokko N, Logvinenko T, Ramachandran N, Godwin AK, Marks J, Engstrom P, LaBaer J. Protein Microarray Signature of Autoantibody Biomarkers for the Early Detection of Breast Cancer. Journal of Proteome Research. 2011 Jan;10(1):85-96.   PMCID: PMC3158028
Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec;117(24):5476-84.   PMCID: not NIH funded
Gu XJ, Jelen U, Li JS, Jia X, Jiang SB. A GPU-based finite-size pencil beam algorithm with 3D-density correction for radiotherapy dose calculation. Physics in Medicine and Biology. 2011 Jun;56(11):3337-50.   PMCID: PMC3144726[Available on 2012/6/7]
Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang XS, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, Dimopoulos AM, Driver WR, Dunnebier T, Durcan L, Eccles D, Edlund CK, Ekici AB, Fasching PA, Feigelson HS, Flesch-Janys D, Fostira F, Forsti A, Fountzilas G, Gerty SM, Giles GG, Godwin AK, Goodfellow P, Graham N, Greco D, Hamann U, Hankinson SE, Hartmann A, Hein R, Heinz J, Holbrook A, Hoover RN, Hu JJ, Hunter DJ, Ingles SA, Irwanto A, Ivanovich J, John EM, Johnson N, Jukkola-Vuorinen A, Kaaks R, Ko YD, Kolonel LN, Konstantopoulou I, Kosma VM, Kulkarni S, Lambrechts D, Lee AM, Le Marchand L, Lesnick T, Liu JJ, Lindstrom S, Mannermaa A, Margolin S, Martin NG, Miron P, Montgomery GW, Nevanlinna H, Nickels S, Nyante S, Olswold C, Palmer J, Pathak H, Pectasides D, Perou CM, Peto J, Pharoah PD, Pooler LC, Press MF, Pylkas K, Rebbeck TR, Rodriguez-Gil JL, Rosenberg L, Ross E, Rudiger T, Silva ID, Sawyer E, Schmidt MK, Schulz-Wendtland R, Schumacher F, Severi G, Sheng X, Signorello LB, Sinn HP, Stevens KN, Southey MC, Tapper WJ, Tomlinson I, Hogervorst FB, Wauters E, Weaver J, Wildiers H, Winqvist R, Van Den Berg D, Wan P, Xia LY, Yannoukakos D, Zheng W, Ziegler RG, Siddiq A, Slager SL, Stram DO, Easton D, Kraft P, Henderson BE, Couch FJ. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature genetics. 2011 Dec;43(12):1210-U61.   PMCID: PMC3279120[Available on 2012/12/1]
Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR. LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer. Cancer Research. 2010 Mar;70(6):2296-306.   PMCID: PMCID: PMC2869247 [Available on 2011/3/15]
Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram. Journal of Clinical Oncology. 2010 Jan;28(2):311-7.   PMCID: PMC2815719
Li H, Cai Q, Godwin AK, Zhang RG. Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells. Molecular Cancer Research. 2010 Dec;8(12):1610-8.   PMCID: PMC3059727[Available on 2011/12/1]
Dong XY, Guo P, Boyd J, Sun XD, Li QN, Zhou W, Dong JT. Implication of snoRNA U50 in human breast cancer. Journal of Genetics and Genomics. 2009 Aug;36(8):447-54.   PMCID: PMCID: PMC2854654
Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating Tumor Cells: Evolving Evidence and Future Challenges. The oncologist. 2009 Jan;14(11):1070-82.   PMCID: not NIH funded
Stefanek ME, Andrykowski MA, Lerman C, Manne S, Glanz K, Aacr Behav Sci Task Force; AACR Behav Sci Task Force. Behavioral Oncology and the War on Cancer: Partnering with Biomedicine. Cancer Research. 2009 Sep;69(18):7151-6.
Astrinidis A, Senapedis W, Henske EP. Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner. Human molecular genetics. 2006 Jan 15;15(2):287-97.
de Caceres, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. CANCER RESEARCH. 2006 May;66(10):5021-8.
Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. ONCOGENE. 2006 Mar;25(11):1602-11.
Pollack A. Is pretreatment PSA velocity associated with pro state-cancer-specific mortality rate after radiotherapy? Commentary. Nature Clinical Practice Urology. 2006 Jan;3(1):13.
Fernandez SV, Russo IH, Lareef M, Balsara B, Russo J. Comparative genomic hybridization of human breast epithelial cells transformed by estrogen and its metabolites. International Journal of Oncology. 2005 Mar;26(3):691-5.
Xiao A, Yin CY, Yang CY, Di Cristofano A, Pandolfi PP, Van Dyke T. Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Research. 2005 Jun 15;65(12):5172-80.   PMCID: not NIH funded
Buyyounouski MK, Hanlon AL, Price RA, Horwitz EM, Feigenberg SJ, Pollack A. In regard to Selek et al. Erectile dysfunction and radiation dose to penile base structures: A lack of correlation (Int J Radiat Oncol Biol Phys) 2004;59 : 1039-1046. International Journal of Radiation Oncology Biology Physics. 2004 Dec;60(5):1664-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term prostate-cancer

prostate-cancer carcinoma gene expression group protein ezh2 histone methyltransferase activity embryonic stem-cells tumor-suppressor gene gene-expression estrogen cell lung-cancer colorectal-cancer epithelial-cells breast cancer snoRNA protein-kinase plan optimization cell transformation inducible factor-i cell-lines natural-history rising incidence dna-repair rna methylation life expectancy adjuvant chemotherapy regions graphics hardware squamous-cell carcinoma dna methylation specificity hamster tissues senescence receptor cell-cycle regulation 4-OH-E-2 controlled-trial v79 cells re-optimization lhermitte-duclos-disease 1985 carty ks-archives of pathology & laboratory medicine-v109-p716 distinct regions candidate kinase c-zeta dietary modification trial risk tumor-antigens resistant marker radical nephrectomy enhancer active surveillance adaptive radiation-therapy smoking-cessation cervical-cancer e-cadherin glioblastoma cells Prostate cancer mammographic density cell-cycle arrest human epidermal growth factor receptor 2 deformable image registration messenger-rna signaling pathways ovarian-cancer ct decision-making histone methyltransferase ezh2 heterozygosity of-life care bulb Oncology interfractional anatomic changes clinical-significance developmental regulators 6q tumor-suppressor genes genomic analyses 1986 carty ks-cancer research-v46-p4244 metastases s-phase supportive oncology central anticholinergic syndrome dependent kinase inhibitor delayed intervention Colon cancer polymerase-chain-reaction carcinogenesis progression-free codon 72 polymorphism tuberous sclerosis gene U50 younger women ezh2 group-complexes promoter hypermethylation identifies 5 online modification imrt treatment MDM2 waf1-polymorphism-apoptosis carcinomas women familial breast-cancer inflammatory breast cancer plk1 prognostic nomogram autoantibodies breast cancer-biomarker-proteomics-protein microarrays cigarette-smoking frequent loss germ-line polymorphisms therapy susceptibility loci unrealistic expectations zeste homolog-2 src family kinases postmenopausal women inhibits growth hormone-levels american society chromatin allelic loss human hepatocellular-carcinoma cdna libraries sensitivity survival cell-death physical-activity cpg-island methylation pluripotent human colorectal-cancer Breast cancer nasopharyngeal carcinoma centrosomes CGH predict survival hormone-replacement therapy humoral immune-response enhancer of zeste homolog 2 ki-67 expression aldehyde dehydrogenase quantitative-analysis aberrant dna methylation tumor suppressor gene tumor progression clinical oncology Circulating tumor cells disease p21 p53 histone deacetylase inhibition
Last updated on Thursday, August 02, 2018